Claritev Corp reports results for the quarter ended June 30 - Earnings Summary
Claritev Corp reports results for the quarter ended June 30 - Earnings Summary
Claritev Corp CTEV.N reported a quarterly adjusted loss of $3.49 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.81. The mean expectation of six analysts for the quarter was for a loss of $4.13 per share. Wall Street expected results to range from $-4.42 to $-3.95 per share.
Revenue rose 6.6% to $257.48 million from a year ago; analysts expected $244.81 million.
Claritev Corp's reported EPS for the quarter was a loss of $3.49.
The company reported a quarterly loss of $59.23 million.
Claritev Corp shares had fallen by 21.3% this quarter and lost 37.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the business support services peer group is also "buy"
Wall Street's median 12-month price target for Claritev Corp is $37.50, about 28.4% above its last closing price of $26.84
This summary was machine generated from LSEG data August 7 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -4.13 | -3.49 | Beat |
Mar. 31 2026 | -4.01 | -4.41 | Missed |
Dec. 31 2025 | -3.81 | -4.88 | Missed |
Sep. 30 2025 | -3.59 | -4.23 | Missed |
Recent news on Claritev
See all newsTPG explores $5 billion sale of healthcare software company Lyric, sources say
Brief: Marpai Expands Relationship With Claritev To Help Reduce Healthcare Costs For Employer Clients
Claritev Corp reports results for the quarter ended June 30 - Earnings Summary
Claritev Q2 revenue and adj EBITDA beat estimates, raises 2026 outlook
Brief: Claritev Corp Q2 Revenue USD 257.478 Million Vs. IBES Estimate USD 244.8 Million